NS-229 is an investigational selective Janus kinase 1 inhibitor designed to prevent tissue damage caused by EGPA by suppressing immune cell activation.

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

After 3 initial monthly injections, current dosing intervals range from every 8 to 16 weeks in patients with wAMD and DME and every 8 to 12 weeks in patients with DR.

Overall, 2679 pregnancy-related deaths could have been prevented if the national rate was reduced to the lowest state rate.

“Midafternoon dosing of inhaled beclomethasone dipropionate better improved nocturnal lung function and inflammatory biomarkers compared with the alternative dosage timings without additional adrenal ...

Poor communication contributed to 24% of safety incidents in 42 studies that examined its contribution along with other causes.

HealthDay News — A senior government health researcher has announced his retirement, accusing the National Institutes of Health (NIH) of censoring his latest findings on ultra-processed food. Kevin ...

Seven recommendations developed, including use of floating immunoreactive trypsinogen cutoff over fixed cutoff.

Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...

In this younger patient population, diazepam nasal spray was readily absorbed and demonstrated a consistent PK profile with that of older children and adults aged 6 to 59 years.

For the first time since 2016, I enjoyed time with friends and family without planning around dialysis treatments,” the patient said in a statement.

To achieve these ends, the FDA will use computer modeling and artificial intelligence (AI) to predict a drug’s behavior and promote the use of lab-grown human organoids (tiny, self-organized ...